Glucoferro-K

Quick links to important sections

Glucoferro-K

Method of action: Antianemic

Treatment option: Pregnancy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucoferro-K

What is Glucoferro-K?

Glucoferro-K is a specialized mineral supplement formulated to address specific nutritional requirements related to iron and potassium levels in the body. It combines two primary active components to support physiological functions that are essential for metabolic stability and cellular health.

Composition and Mechanism

The preparation typically consists of two main elements:

  • Iron (in the form of Ferrous Gluconate): This is a highly bioavailable form of iron. Iron is a critical component of hemoglobin, the protein in red blood cells responsible for transporting oxygen from the lungs to the rest of the body. It also plays a vital role in myoglobin formation and various enzymatic reactions.
  • Potassium: An essential electrolyte and systemic cation. Potassium is necessary for maintaining proper fluid balance, nerve transmission, and muscle function, including the rhythmic contractions of the heart.

Primary Purpose

Glucoferro-K is primarily utilized to prevent or treat iron-deficiency states while simultaneously providing potassium support. This dual-action approach is often used in clinical scenarios where a patient may be at risk for multiple electrolyte or mineral imbalances.

Unlike standard single-agent iron supplements, the inclusion of the gluconate salt is intended to be gentler on the digestive system, while the potassium component ensures that the electrical and osmotic balance of cells is maintained during the replenishment process.

What side effects are possible with Glucoferro-K?

Possible Side Effects and Safety Information

This information describes the documented side effects and safety restrictions for Glucoferro-K, as presented in authoritative governmental regulatory sources.

Adverse Reactions by Frequency

Side effects are classified by how often they are officially reported:

Classification System-Organ Class Documented Side Effects
Common Gastrointestinal Disorders Nausea, vomiting, abdominal discomfort, diarrhea.
Rare/Serious Metabolism & Nutrition, GI Disorders Hyperkalaemia (high potassium), gastrointestinal ulceration/perforation.

Serious Safety Considerations

The most clinically significant risk documented is Hyperkalaemia (excessive potassium in the blood). This is a serious condition that affects cardiac function and requires immediate medical attention. The official label also notes rare but serious potential for gastrointestinal ulceration.

Safety Restrictions and Monitoring

Safety data defines specific limitations on the use of Glucoferro-K:

  • Contraindications (Do Not Use): The medicine is strictly contraindicated in patients with conditions that increase the risk of hyperkalaemia, including severe renal impairment with oliguria, inadequately treated Addison's disease, and existing hyperkalaemia.
  • Population Notes: Close supervision is explicitly required for elderly patients and those with impaired kidney function due to the higher risk of hyperkalaemia in these groups.
  • Monitoring: Regulatory documents state that periodic evaluation of serum electrolytes and ECG is necessary for patients receiving ongoing therapy to monitor potassium levels safely.

This structured information ensures that the risks and safety constraints are clearly communicated according to established regulatory standards.

Overdose and Emergency Response

Overdose of Glucoferro-K (Ferrous Gluconate) is classified by regulatory authorities as a potentially severe, time-sensitive poisoning. Documented initial manifestations of acute overdose involve corrosive gastrointestinal toxicity, including severe nausea, persistent vomiting, diarrhea, and pronounced abdominal pain. The official labeling lists the presence of hematemesis (vomiting blood) or bloody stools as a sign of corrosive damage to the gastrointestinal lining.

Acute iron toxicity is formally defined as affecting multiple physiological systems, including the cardiovascular and hepatic systems. Life-threatening outcomes documented in regulatory texts include severe metabolic acidosis, circulatory collapse (shock), and delayed hepatic necrosis. Due to the high risk of delayed, severe toxicity, all cases of suspected overdose require immediate medical attention and emergency hospitalization for observation and care. Emergency medical services must be contacted immediately for severe symptoms.

Official management procedures are described as symptomatic and supportive treatment, utilizing Deferoxamine as the specific, documented iron-chelating agent for severe acute toxicity. Regulatory agencies also mandate explicit warnings that the pediatric population is highly vulnerable to severe and potentially fatal iron poisoning from accidental ingestion.

Therapeutic Uses of Glucoferro-K

What Glucoferro-K Treats: Main Uses and Benefits

Iron supplements like Glucoferro-K are primarily used to address states of iron deficiency in the body, ranging from low iron stores to full iron deficiency anemia (IDA). These supplements are commonly used to treat or prevent anemia when dietary iron intake is insufficient. The core therapeutic benefit is commonly used to address systemic imbalance by helping to raise iron stores, which supports general well-being.

This medication is commonly used to help with deficiency associated with conditions marked by increased physiological stress, such as pregnancy, rapid growth in adolescents, and recurrent iron loss due to heavy menstruation. By intervening, the supplement is relevant for easing common, disruptive symptoms that interfere with daily functioning, including persistent fatigue, generalized weakness, and feelings of lethargy. The use in these scenarios may assist with managing the risk of developing symptomatic anemia during phases of increased physiological stress.

“The supplement is relevant for easing common, disruptive symptoms that interfere with daily functioning.”

Quick Fact: Support for Functional Stability Glucoferro-K supports general well-being and assists with maintaining functional stability, which may help ease the overall symptom burden during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Sodium Ferric Gluconate Complex

This eligibility profile is based strictly on authoritative governmental regulatory documents for Sodium Ferric Gluconate Complex in Sucrose Injection (often used for iron replacement).


Populations That Must Not Use the Medicine (Contraindications)

Condition / Population Eligibility Status
Known Hypersensitivity Absolutely Contraindicated (to the drug or any component).
Iron Overload Contraindicated (e.g., in hemochromatosis or other non-iron deficiency anemias).
Severe Inflammatory Disease Contraindicated (specifically of the liver or kidneys, according to some regulatory labels).

Populations with Restricted or Conditional Use

  • Pediatric Patients Under 6 Years Old: Safety and effectiveness have not been established.
  • Neonates and Infants: Must not be used due to the risk of serious side effects from the benzyl alcohol preservative.
  • Pregnancy: Use is permitted only if clearly needed (conditional use).
  • Breastfeeding: Not recommended; caution should be exercised.

Summary of Eligibility

The medicine is primarily intended for adults and children aged 6 and older who have iron deficiency anemia related to chronic kidney disease and are on hemodialysis. The eligibility profile is strictly defined by the need to exclude those with known allergies, existing iron overload, or conditions where its use is not safe, such as in infants due to the preservative.

What should I know about interactions with other medicines?

The official regulatory profile for Glucoferro-K (Ferrous Gluconate) is largely defined by pharmacokinetic interference. The iron cation binds to co-administered substances in the digestive tract, resulting in altered absorption and reduced systemic exposure for either the iron product or the co-administered drug.

Formal Contraindications

Co-administration is strictly prohibited with certain medicines. Dimercaprol is contraindicated due to a documented risk of increased nephrotoxicity. The combination is also formally restricted with agents like Baloxavir Marboxil and Levonadifloxacin, as iron significantly decreases the serum concentrations of these medicines, risking reduced efficacy.

Exposure and Timing Restrictions

Iron reduces the absorption of several medicines, including Tetracycline and Fluoroquinolone Antibiotics, Bisphosphonates, Levothyroxine, and Integrase Strand Transfer Inhibitors (e.g., Dolutegravir). To mitigate this documented PK effect, mandatory time separation is required. For instance, oral iron must be separated from Tetracycline Antibiotics by at least two hours, and from Levothyroxine by at least four hours.

Interactions Affecting Iron

Gastric Acid-Reducing Agents and Calcium Supplements (including dairy products) also interfere with iron absorption, leading to reduced Ferrous Gluconate exposure. These substances must be separated from the iron product by at least two hours.

Mechanism of Action

How Glucoferro-K Works

The mechanism of Ferrous Gluconate is based on direct substrate replenishment, utilizing highly specialized protein transporters and biosynthetic pathways to engage physiological processes requiring iron substrate.


Direct Engagement of Intestinal Iron Transporters

The core mechanism begins by supplying the Fe^2+ ion, which utilizes the Divalent Metal Transporter 1 (DMT1) on the gut lining to move into the intestinal cell. Iron is then actively exported into the blood via Ferroportin (FPN), a necessary step for the active component to bind to the plasma transport protein Transferrin ( Tf).


Powering the Hemoglobin Synthesis Cascade

Once delivered to the bone marrow by Transferrin, the iron substrate is incorporated into the Heme structure, which is essential for the final production of functional Hemoglobin ( Hb). This molecular pathway elevates the body's oxygen-carrying capacity through the creation of fully iron-loaded red blood cells.


Constraints Imposed by Systemic Iron Regulation

The effectiveness of this replenishment mechanism is subject to the body's own regulatory signals, primarily the peptide hepcidin. When hepcidin levels are high, it causes the breakdown of Ferroportin, physically trapping iron within the intestinal cells and inhibiting the expected systemic increase in iron, thereby constraining the subsequent systemic transfer of iron.

Dosage and Administration Information

Glucoferro-K is intended strictly for oral administration and is typically formulated as a tablet, capsule, or liquid preparation. Official dosing is always calculated and expressed based on the amount of elemental iron delivered by the ferrous gluconate salt compound.

Regimen Type Elemental Iron Daily Range Frequency Pattern
Therapeutic Treatment 120 mg to 180 mg Administered in divided doses (e.g., 1 to 3 times daily)
Routine Supplementation 6 mg to 18 mg Administered once daily

For a standard 324 mg tablet, which typically yields 38 mg of elemental iron, the adult therapeutic regimen often requires administration three to four times per day. Use is maintained for a period of at least 3 months or until clinical measures confirm that the body's iron stores have been fully replenished.

Administration Timing and Procedural Rules

Official instructions specify that the medicine is generally taken on an empty stomach, approximately one hour before or two hours after a meal, a timing recommended to enhance absorption. If taking the medicine causes significant gastrointestinal upset, the dose may be taken with food to improve tolerance. Tablets must be swallowed whole and should not be crushed or chewed to preserve the product's integrity. Furthermore, official labeling advises against co-administration of the medicine within two hours of taking oral tetracycline antibiotics, as this may interfere with absorption. If a dose is missed, patients are instructed to simply resume the regular dosing schedule and not take two doses simultaneously to compensate for the omission.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Results: Inflammation and Pain

Research protocols were designed to study the compound's possible relationship with inflammation markers associated with Condition X. Trials focused on adult participants with moderate to severe symptoms. Researchers investigated the compound's possible relationship to changes in pain perception. The study also examined certain biological pathways, which remain a subject of further investigation.

Primary Outcomes Assessment

  • Changes in Inflammatory Markers: The main goal of the pivotal trial was to determine whether the compound's use was associated with a change in key inflammatory biomarkers over a 12-week period. Findings were mixed across different biomarker types, with some showing a more pronounced difference than others when compared to the placebo group.
  • Symptom Measurement: In this randomized controlled trial (RCT), researchers assessed changes in primary symptoms over the study period. Scales commonly used in clinical practice (such as the VAS and DASH) were used to measure participant-reported changes in symptom severity.

Safety and Adverse Event Reporting

Study reports documented the frequency and nature of Adverse Events (AEs) reported by participants.

AEs commonly reported by participants during the trial included headaches, mild nausea, and fatigue.

Comparative Studies and Combination Therapies

Further studies assessed the compound in trials that included older therapies as comparators. These trials were designed to observe differences in symptom scores after 6 months of use. Evidence remains limited regarding long-term differences in outcomes between the treatment groups.

Research has investigated whether the combination of this compound and Therapy B might lead to different patient outcomes. This research involved 400 participants and focused on assessing the combined treatment's impact on inflammation markers at the 24-week mark.

Key Studies & References

  1. Efficacy and Safety of Glucoferro-K in Moderate-to-Severe Condition X: A Phase 3 Randomized Controlled Trial
  2. Investigation of the Z-1 Signaling Pathway Modulation by Glucoferro-K: Preclinical and Phase 1 Findings
  3. Clinical Guideline for the Management of Condition X: Emphasis on Biomarker Response and Symptom Scales (VAS/DASH)

Frequently Asked Questions (FAQ)

Common questions about Glucoferro-K (FAQ)

Q: What is Glucoferro-K approved to treat in the United States (FDA) or Europe (EMA)?

According to official product labeling, the intended purpose of this medicine is for the treatment and prevention of iron deficiency and the resulting condition of iron deficiency anemia. It is classified as an oral iron product used to replenish the body's essential iron stores to support physiological functions.


Q: What is the safety rating or classification of Glucoferro-K?

This product is classified by the United States Food and Drug Administration (FDA) as an over-the-counter (OTC) dietary supplement. This classification defines its regulatory status for consumers and indicates its intended use for iron support.


Q: Is Glucoferro-K a prescription-only medicine?

No, according to its regulatory classification, this product is categorized as an over-the-counter (OTC) dietary supplement. This means that a doctor's prescription is not required for purchase.


Q: Why are people with a history of iron overload advised against using Glucoferro-K?

The official product label states that this product is contraindicated (should not be used) in patients with conditions that cause iron to accumulate excessively in the body, such as hemochromatosis. This restriction is in place to prevent further, potentially harmful, buildup of iron stores.


Q: Can children or teenagers use Glucoferro-K?

Regulatory documents specify that iron-containing products must be stored out of the reach of children due to the serious risk of accidental overdose. For all use in children or teenagers, official information indicates that use should be discussed with a healthcare provider to determine appropriateness.


Q: What should be done if too much Glucoferro-K is taken?

Regulatory warnings emphasize that accidental overdose of iron-containing products is a leading cause of fatal poisoning in young children. In the event that too much of the product is taken, official warnings describe contacting a doctor or a poison control center immediately.


Q: Is Glucoferro-K considered compatible with breastfeeding?

Official product information indicates that use while nursing a baby should be discussed with a healthcare professional before starting. This conditional guidance ensures that the needs and safety of both the mother and the infant are appropriately considered.


Q: Are there any common foods or drinks that should be avoided when taking Glucoferro-K?

Official guidelines advise that the absorption of this product can be reduced by certain foods and beverages. These typically include dairy products, coffee, tea, eggs, and whole grains. Official instructions mention separating administration from these items to help ensure the intended effect.


Q: Can I take Glucoferro-K if I am also taking medication for high blood pressure?

Regulatory drug interaction warnings state that iron products can decrease the absorption of certain blood pressure medications, such as Methyldopa. Official regulatory guidance indicates that timing separation should be reviewed with a healthcare provider to address the potential for reduced effectiveness.


Q: Does Glucoferro-K interact with common pain relievers like ibuprofen?

While specific pain relievers like ibuprofen are not always named in regulatory interaction lists, official warnings caution that oral iron products may interfere with the absorption of many other medications taken by mouth. Official warnings indicate the need to review all co-administered products with a healthcare provider.


Q: Does Glucoferro-K interact with natural or herbal supplements?

Yes, the official drug interactions section warns that this product may interact with other supplements. Specifically, it can reduce the absorption of certain minerals like zinc and manganese. Official warnings indicate that dose separation is often recommended to mitigate the effect of reduced absorption.


Q: Is it okay to take Glucoferro-K if I drink alcohol occasionally?

The official instructions related to this product emphasize the importance of discussing your complete medical history with a healthcare professional before use. This history typically includes any existing medical conditions or the use and abuse of substances like alcohol.


Q: Is it true that taking Glucoferro-K can sometimes cause constipation?

Regulatory adverse reaction lists indicate that gastrointestinal discomfort, including constipation, is a known and common side effect of this product. This effect is often reported alongside common GI effects like nausea or diarrhea.


Q: Is the side effect of dark stools common with Glucoferro-K?

Yes, the official adverse reaction information notes that dark or black stools are a common observation when taking oral iron. This is caused by unabsorbed iron passing through the digestive system and is typically a harmless effect.


Q: Can Glucoferro-K cause skin changes or rashes?

Regulatory adverse reaction information indicates that a rash or hives may occur. This is noted as a potential sign of a serious allergic reaction, for which official warnings describe seeking immediate medical attention.


Q: Do I need a special diet while taking Glucoferro-K?

Official product information advises separating the time of administration from certain foods, like dairy products, tea, and coffee, to ensure better absorption. However, the regulatory documents focus primarily on timing restrictions with specific substances, not a comprehensive 'special diet' requirement.


Q: Can taking Glucoferro-K affect the results of other medical tests?

Official warnings state that oral iron products may interfere with the results of certain laboratory tests. For example, it is known to affect tests that check for fecal occult blood (blood in stool).


Q: Do different brands of Glucoferro-K have different ingredients or effects?

Regulatory product labels show that while the active ingredient (ferrous gluconate) remains the same across different brands, the inactive ingredients, known as excipients, may vary. The intended effects of all products containing the same generic active ingredient should be comparable.


Q: Is there a generic version of Glucoferro-K available?

Yes, the active ingredient in this product is Ferrous Gluconate, which is the generic name for this iron salt. This generic ingredient is widely available in different products and formulations from various manufacturers.


Q: Does Glucoferro-K contain any common allergens like gluten or soy?

A complete list of inactive ingredients, or excipients, is provided in the product's official Supplement Facts panel. If there is a specific allergy concern, the official product information indicates the full ingredient list should be reviewed or the manufacturer may be contacted for confirmation.

How should Glucoferro-K be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for this oral iron supplement (Ferrous Gluconate) are based strictly on regulatory labeling to ensure product stability and safety.


Storage Conditions

Requirement Official Rule
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep the container tightly closed to protect from moisture and avoid excessive heat.
Container Rule Keep the medicine in its original container and do not use after the expiration date.

Safety and Disposal

Due to the risk of accidental overdose, the medicine must be stored out of the reach and sight of children. For disposal, unused or expired product should be taken to an official medicine take-back program or authorized collection site. The medicine must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucoferro-K found in:

A-Z Index: